---
schema_version: "secwatch.filing_event.v1"
accession: "0001798749-24-000036"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2024-06-28T23:59:59+00:00"
generated_at: "2026-06-01T00:45:07.576265+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aerovate Therapeutics cuts 78% of workforce after halting AV-101 trial

## Summary
- Reduction follows shutdown of Phase 2b/3 trial of AV-101 and long-term extension study.
- First wave terminates 39 employees (78% of workforce); nearly all remaining staff to follow.
- Estimated severance costs of $5.6 million, expected in Q3 and Q4 2024.
- Severance contingent on separation agreement with general release of claims.

## SEC filing metadata
- accession: 0001798749-24-000036
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2024-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000179874924000036/0001798749-24-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000179874924000036/tmb-20240625x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001798749-24-000036
- JSON: https://secwatch.observer/filing/0001798749-24-000036.json
- Plain text: https://secwatch.observer/filing/0001798749-24-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.